ChemoMetec ASOCSE:CHEMM -1.12%99 PS Ratio is 14.29 as of Jul. 08, 2026, which is 22% below its 10-year median of 18.25. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr550.18 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 88.07% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ChemoMetec AS's share price is kr405.00.
ChemoMetec AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr28.33. Hence, ChemoMetec AS's PS Ratio for today is 14.29.
The historical rank and industry rank for ChemoMetec AS's PS Ratio or its related term are showing as below:
OCSE:CHEMM'
s PS Ratio Range Over the Past 10 Years
Min: 4.56 Med: 18.25 Max: 67.6
Current: 14.3
During the past 13 years, ChemoMetec AS's highest PS Ratio was 67.60. The lowest was 4.56. And the median was 18.25.
OCSE:CHEMM's PS Ratio is ranked worse than 88.07% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs OCSE:CHEMM: 14.30
ChemoMetec AS revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of ChemoMetec AS was 7.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 23.30% per year.
During the past 13 years, ChemoMetec AS's highest 3-Year average Revenue per Share Growth Rate was 31.70% per year. The lowest was -86.80% per year. And the median was 16.85% per year.
Back to Basics: PS Ratio
ChemoMetec AS (OCSE:CHEMM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ChemoMetec AS PS Ratio Related Terms
ChemoMetec AS PS Ratio Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ChemoMetec AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ChemoMetec AS's Share Price of today is kr405.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr28.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ChemoMetec AS (OCSE:CHEMM) has a PS Ratio of 14.29 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ChemoMetec AS and its competitors. This is 22% below median its historical median of 18.25. Over the past decade, ChemoMetec AS's PS Ratio has ranged from 4.56 to 67.60. According to the industry distribution chart, ChemoMetec AS ranks #709 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 88.1%.
Is ChemoMetec AS's PS Ratio too high?
ChemoMetec AS's current PS Ratio of 14.29 is 22% below median its 10-year median of 18.25. Over the past 10 years, this metric has ranged from a low of 4.56 to a high of 67.60. The Medical Devices & Instruments industry median PS Ratio is 2.94. ChemoMetec AS's value of 14.29 is 386.1% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #709 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #709 out of 805 companies for PS Ratio. This places ChemoMetec AS in the lower half of its industry. The industry median PS Ratio is 2.94. ChemoMetec AS's value of 14.29 is 386.1% above this benchmark. Historically, ChemoMetec AS's own PS Ratio has ranged from 4.56 to 67.60 over the past decade. While the company's 10-year median is 18.25 vs. the industry median of 2.94, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current PS Ratio of 14.29 is 386.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current PS Ratio is 14.29, which is 22% below median its own 10-year median of 18.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr550.18, compared to a current price of kr405.00 — trading 26.4% below its estimated fair value. The current PS Ratio is 14.29, which is 22% below median its 10-year median of 18.25 and 386.1% above the Medical Devices & Instruments industry median of 2.94. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current PS Ratio is 14.29 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr405.00 is trading 26.4% below its estimated GF Value™ of kr550.18.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
PS Ratio: 14.29 (22% below median its 10-year median of 18.25)
GF Value™: kr550.18 vs. price of kr405.00 (26.4% below fair value)
Industry Position: 386.1% above the Medical Devices & Instruments median (#709 of 805)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
